Neurocrine BiosciencesNBIX
About: Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Employees: 1,800
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 108 | Existing positions closed: 72
20% more funds holding in top 10
Funds holding in top 10: 10 [Q3] → 12 (+2) [Q4]
19% more capital invested
Capital invested by funds: $10.8B [Q3] → $12.9B (+$2.03B) [Q4]
4% more funds holding
Funds holding: 564 [Q3] → 585 (+21) [Q4]
9% more call options, than puts
Call options by funds: $48M | Put options by funds: $44.2M
4% more repeat investments, than reductions
Existing positions increased: 213 | Existing positions reduced: 204
0.01% more ownership
Funds ownership: 93.2% [Q3] → 93.21% (+0.01%) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
JP Morgan Anupam Rama 28% 1-year accuracy 17 / 61 met price target | 64%upside $184 | Overweight Maintained | 26 Mar 2025 |
Morgan Stanley Jeffrey Hung 37% 1-year accuracy 10 / 27 met price target | 33%upside $150 | Overweight Assumed | 7 Mar 2025 |
HC Wainwright & Co. Andrew Fein 34% 1-year accuracy 121 / 355 met price target | 65%upside $185 | Buy Reiterated | 24 Feb 2025 |
Guggenheim Yatin Suneja 31% 1-year accuracy 10 / 32 met price target | 45%upside $163 | Buy Maintained | 10 Feb 2025 |
RBC Capital Brian Abrahams 19% 1-year accuracy 13 / 70 met price target | 32%upside $148 | Sector Perform Maintained | 7 Feb 2025 |
Financial journalist opinion
Based on 7 articles about NBIX published over the past 30 days









